

David R Fogelman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4341247/publications.pdf>

Version: 2024-02-01

78
papers

2,739
citations

172386

29
h-index

189801

50
g-index

80
all docs

80
docs citations

80
times ranked

4607
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with <i>BRAF</i> V600E Mutation. <i>Cancer Discovery</i> , 2016, 6, 1352-1365.	7.7	192
2	Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. <i>Drug Design, Development and Therapy</i> , 2015, 9, 5075.	2.0	160
3	Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 2416-2423.	0.7	125
4	Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 164-174.	0.9	124
5	Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. <i>Lancet Oncology</i> , The, 2015, 16, 695-703.	5.1	111
6	Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With <i>BRAF</i> -Mutated Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2014, 13, 164-171.	1.0	108
7	Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. <i>JAMA Surgery</i> , 2020, 155, 832.	2.2	105
8	The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 61, 167-175.	1.1	82
9	Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. <i>JAMA Surgery</i> , 2017, 152, 1048.	2.2	82
10	Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer. <i>Anticancer Research</i> , 2011, 31, 1417-20.	0.5	78
11	<i>FBXW7</i> missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 39268-39279.	0.8	69
12	Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. <i>PLoS ONE</i> , 2017, 12, e0173345.	1.1	65
13	Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. <i>Annals of Surgery</i> , 2021, 273, 806-813.	2.1	61
14	Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 489-498.	1.1	59
15	Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. <i>Cancer Cell</i> , 2018, 33, 752-769.e8.	7.7	58
16	Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline <i>BRCA</i> Variants. <i>JAMA Oncology</i> , 2021, 7, 693.	3.4	56
17	Home-based exercise during preoperative therapy for pancreatic cancer. <i>Langenbeck's Archives of Surgery</i> , 2017, 402, 1175-1185.	0.8	52
18	Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4146-4154.	3.2	50

#	ARTICLE	IF	CITATIONS
19	Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1924-1931.	3.2	50
20	Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. <i>Cancer</i> , 2016, 122, 2671-2679.	2.0	49
21	Physical activity and exercise during preoperative pancreatic cancer treatment. <i>Supportive Care in Cancer</i> , 2019, 27, 2275-2284.	1.0	45
22	The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy. <i>Annals of Surgical Oncology</i> , 2015, 22, 1221-1228.	0.7	44
23	Exercise during preoperative therapy increases tumor vascularity in pancreatic tumor patients. <i>Scientific Reports</i> , 2019, 9, 13966.	1.6	43
24	Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. <i>Oncotarget</i> , 2016, 7, 67495-67506.	0.8	42
25	Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 1975-1985.	0.9	42
26	Anthropometric Changes in Patients with Pancreatic Cancer Undergoing Preoperative Therapy and Pancreatoduodenectomy. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 703-712.	0.9	39
27	Role of Neoadjuvant Therapy in the Multimodality Treatment of Older Patients with Pancreatic Cancer. <i>Journal of the American College of Surgeons</i> , 2014, 219, 111-120.	0.2	36
28	Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. <i>Cancer Medicine</i> , 2021, 10, 5041-5050.	1.3	35
29	Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. <i>Annals of Surgery</i> , 2020, 271, 996-1002.	2.1	34
30	Retrospective analysis of systemic chemotherapy and total parenteral nutrition for the treatment of malignant small bowel obstruction. <i>Cancer Medicine</i> , 2016, 5, 239-247.	1.3	33
31	Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer. <i>Cancer Medicine</i> , 2018, 7, 5382-5393.	1.3	32
32	Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. <i>British Journal of Cancer</i> , 2019, 121, 505-510.	2.9	32
33	Association between frailty syndrome and survival in patients with pancreatic adenocarcinoma. <i>Cancer Medicine</i> , 2019, 8, 2867-2876.	1.3	32
34	Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1385-1394.	3.2	31
35	Comprehensive Clinical and Molecular Characterization of KRAS ^{G12C} -Mutant Colorectal Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 613-621.	1.5	31
36	Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater. <i>Annals of Surgical Oncology</i> , 2017, 24, 2031-2039.	0.7	30

#	ARTICLE	IF	CITATIONS
37	Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma. <i>Journal of Hematology and Oncology</i> , 2018, 11, 71.	6.9	30
38	Randomized Controlled Trial Of Dalteparin For Primary Thromboprophylaxis For Venous Thromboembolism (VTE) In Patients With Advanced Pancreatic Cancer (APC): Risk Factors Predictive Of VTE. <i>Blood</i> , 2013, 122, 580-580.	0.6	27
39	A predictive model of inflammatory markers and patient-reported symptoms for cachexia in newly diagnosed pancreatic cancer patients. <i>Supportive Care in Cancer</i> , 2017, 25, 1809-1817.	1.0	26
40	Clinical utility of circulating cell-free DNA in advanced colorectal cancer. <i>PLoS ONE</i> , 2017, 12, e0183949.	1.1	25
41	High Prevalence of Hereditary Cancer Syndromes and Outcomes in Adults with Early-Onset Pancreatic Cancer. <i>Cancer Prevention Research</i> , 2018, 11, 679-686.	0.7	25
42	Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab. <i>Cancer</i> , 2014, 120, 1780-1786.	2.0	23
43	An open-label, single-arm pilot study of EUS-guided brachytherapy with phosphorus-32 microparticles in combination with gemcitabine +/- nab-paclitaxel in unresectable locally advanced pancreatic cancer (OncoPaC-1): Technical details and study protocol. <i>Endoscopic Ultrasound</i> , 2020, 9, 24.	0.6	23
44	Joint prognostic effect of obesity and chronic systemic inflammation in patients with metastatic colorectal cancer. <i>Cancer</i> , 2015, 121, 2968-2975.	2.0	22
45	Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX. <i>Pancreas</i> , 2019, 48, 837-843.	0.5	22
46	Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2014, 5, 307-313.	2.9	21
47	Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1431-1438.	1.1	20
48	Novel EUS-guided brachytherapy treatment of pancreatic cancer with phosphorus-32 microparticles: first United States experience. <i>VideoGIE</i> , 2019, 4, 223-225.	0.3	20
49	Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 614-618.	0.6	14
50	Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors. <i>JAMA Oncology</i> , 2022, 8, 904.	3.4	13
51	The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2020, 27, 3939-3947.	0.7	12
52	Emerging drugs for colorectal cancer. <i>Expert Opinion on Emerging Drugs</i> , 2008, 13, 629-642.	1.0	10
53	The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 425-430.	1.1	10
54	Portomesenteric Venous Stenting for Palliation of Ascites and Variceal Bleeding Caused by Prehepatic Portal Hypertension. <i>Oncologist</i> , 2018, 23, 712-718.	1.9	9

#	ARTICLE	IF	CITATIONS
55	Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. <i>Cancer Medicine</i> , 2020, 9, 5406-5415.	1.3	9
56	Should Combination Chemotherapy Serve as the Backbone in Clinical Trials of Advanced Pancreatic Cancer?. <i>Pancreas</i> , 2014, 43, 343-349.	0.5	8
57	First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 619-627.	0.7	8
58	The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer. <i>Investigational New Drugs</i> , 2013, 31, 1375-1383.	1.2	6
59	Dual-Energy X-Ray Absorptiometry Compared to Computed Tomography for Visceral Adiposity Assessment Among Gastrointestinal and Pancreatic Cancer Survivors. <i>Scientific Reports</i> , 2019, 9, 11500.	1.6	5
60	A Randomized, Placebo-Controlled, Double-Blind Study of Minocycline for Reducing the Symptom Burden Experienced by Patients With Advanced Pancreatic Cancer. <i>Journal of Pain and Symptom Management</i> , 2020, 59, 1052-1058.e1.	0.6	5
61	The effect of antibiotic use on survival of patients with resected pancreatic ductal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15773-e15773.	0.8	5
62	A retrospective analysis of antibiotics usage and effect on overall survival and progressive free survival in patients with metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15781-e15781.	0.8	5
63	Trial Sponsorship and Time to Reporting for Phase 3 Randomized Cancer Clinical Trials. <i>Cancers</i> , 2020, 12, 2636.	1.7	4
64	FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. <i>Clinical Colorectal Cancer</i> , 2020, 19, 248-255.e6.	1.0	3
65	Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low Cmax and improved tolerability, in patients with solid tumors. <i>Investigational New Drugs</i> , 2020, 38, 1763-1773.	1.2	3
66	Medical oncology and pancreatic cancer: what the radiologist needs to know. <i>Abdominal Radiology</i> , 2018, 43, 383-392.	1.0	2
67	Phase II study of preoperation mFOLFIRINOX and chemoradiation for high-risk resectable and borderline resectable pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 362-362.	0.8	2
68	FOLFIRINOX in pancreatic cancer patients age 75 years or older.. <i>Journal of Clinical Oncology</i> , 2019, 37, 362-362.	0.8	2
69	Bevacizumab Does Not Influence the Efficacy of Partial Splenic Embolization in the Management of Chemotherapy-Induced Hypersplenism. <i>Clinical Colorectal Cancer</i> , 2020, 19, e189-e199.	1.0	1
70	Proteomic profiling of phosphatidylinositol 3-kinase (PI3K) altered metastatic colorectal cancer (mCRC) after protein kinase B (Akt) inhibition: Insulin like growth factor 1 receptor (IGF1R) mediates adaptive resistance.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3549-3549.	0.8	1
71	High prevalence of hereditary cancer syndromes and outcomes in adults with early-onset pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4129-4129.	0.8	1
72	Evolution of phase 1 trials for patients with advanced pancreatic cancer: An update on the experience from MD Anderson Cancer Center.. <i>Journal of Clinical Oncology</i> , 2015, 33, 320-320.	0.8	0

#	ARTICLE	IF	CITATIONS
73	Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. <i>Oncotarget</i> , 2017, 8, 87163-87173.	0.8	0
74	Cell-free circulating tumor DNA somatic alteration burden and its impact on survival in metastatic cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 12022-12022.	0.8	0
75	The association between female hormonal supplementation and molecular types in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15133-e15133.	0.8	0
76	Phase I study of DFP-11207, a novel oral 5-FU with enhanced PK and improved tolerability, in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3034-3034.	0.8	0
77	FOLFOXIRI versus doublet-regimens in the first-line therapy of MSI-S right-sided (RS) metastatic colorectal cancer (mCRC): A survival analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15060-e15060.	0.8	0
78	Meat consumption and BRAF mutation status in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15135-e15135.	0.8	0